Imagen de Portada

Pharmacological Management of Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a common interstitial lung disease (ILD) caused by environmental exposures, infections, or traumatic injuries and subsequent epithelial damage. Since IPF is a progressively fatal disease without remission, treatment is both urgent and necessary. The two medicat...

Descripción completa

Guardado en:
Autores principales: Panahi, Ladan, Udeani, George, Tenpas, Andrew Scott, Ofili, Theresa, Aguilar, Elizabeth Marie, Burchard, Sarah, Ritenour, Alexandra Ruth, Chennat, April Jacob, Ahmed, Nehal, Atphaisit, Chairat, Chi, Crystal, III, Jesus Cruz, Deleon, Monica D., Lee, Samantha, Mayo, Zack, Mcbeth, Mackenzie, Morales, Mariel, Nwosu, Jennifer N., Palacios, Kelly, Pena, Jaycob M., Vara, Nitza
Formato: Capítulo de libro
Lenguaje:inglés
Publicado: IntechOpen 2021
Materias:
Health Sciences
Acceso en línea:https://www.intechopen.com/chapters/79706
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Sumario:Idiopathic pulmonary fibrosis (IPF) is a common interstitial lung disease (ILD) caused by environmental exposures, infections, or traumatic injuries and subsequent epithelial damage. Since IPF is a progressively fatal disease without remission, treatment is both urgent and necessary. The two medications indicated solely for treatment include the tyrosine kinase inhibitor nintedanib (Ofev®) and the anti-fibrotic agent pirfenidone (Esbriet®). This chapter discusses in detail the current treatment options for clinical management of IPF, specifically the mentioned two pharmacotherapeutic agents that decrease physiological progression and likely improve progression-free survival. The chapter also discusses the evolution of drug therapy in IPF management and the drawbacks and limitations learned throughout historical trials and observational studies.
ISBN:978-1-83969-239-0
DOI:10.5772/intechopen.101390

Ejemplares similares